About: Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study
Creator	Thompson, J Appelbaum, F Bensinger, W Benyunes, M Buckner, C Chauncey, T Fefer, A Lindgren, C Petersdorf, S Press, O Robinson, N York, A
Source	PMC
abstract	The success of autologous stem cell transplantation (ASCT) for hematologic malignancy is limited largely by a high relapse rate. It is postulated that IL-2 administered after ASCT may eliminate minimal residual disease and thereby reduce relapses. A phase I/II study was performed to identify a regimen of IL-2 (Chiron) that could be given early after ASCT in phase III trials. In the phase I study, beginning a median of 46 days after ASCT for hematologic malignancy, cohorts of three to four patients received escalating doses of ‘induction’ IL-2 of 9, 10, or 12 × 10(6) IU/m(2)/day for 4 or 5 days by continuous i.v. infusion (CIV), followed by a 4-day rest period, and then 1.6 × 10(6) IU/m(2)/day of maintenance IL-2 by CIV for 10 days. The maximum tolerated dose (MTD) of induction IL-2 was 9 × 10(6) IU/m(2)/day × 4. In the phase II study, 52 patients received the MTD. Eighty percent of patients completed induction IL-2. Most patients exhibited some degree of capillary leak. One patient died of CMV pneumonia and one died of ARDS. Maintenance IL-2 was well tolerated. In the phase I/II study, 16 of 31 patients with non-Hodgkin lymphoma (NHL), 3/8 with Hodgkin disease (HD), 4/17 with AML, and 4/5 with ALL remain in CR. Two of six multiple myeloma (MM) patients remain in PR. Although the regimen of IL-2 identified had significant side-effects in some patients, it was well tolerated in the majority of patients. Phase III prospectively randomized clinical trials are in progress to determine if this IL-2 regimen will decrease the relapse rate after ASCT for AML and NHL.
has issue date	1997-12-18(xsd:dateTime)
bibo:doi	10.1038/sj.bmt.1700687
bibo:pmid	9052908
has license	no-cc
sha1sum (hex)	95004cd43f731cf90a3b02353eb1ff77fc2e5784
schema:url	https://doi.org/10.1038/sj.bmt.1700687
resource representing a document's title	Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study
has PubMed Central identifier	PMC7092324
has PubMed identifier	9052908
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:95004cd43f731cf90a3b02353eb1ff77fc2e5784#body_text
is schema:about of	named entity 'Interleukin-2' named entity 'EARLY' named entity 'transplantation' named entity 'ASCT' named entity 'immunotherapy' named entity 'interleukin-2' named entity 'Interleukin-2' named entity 'hematologic malignancy' covid:arg/95004cd43f731cf90a3b02353eb1ff77fc2e5784 named entity 'immunotherapy' named entity 'IL-2' named entity 'INTERLEUKIN-2 ' named entity 'MINIMAL RESIDUAL DISEASE' named entity 'RELAPSE RATE' named entity 'ADMINISTERED' named entity 'phase I/II' named entity 'TIME' named entity 'minimal residual disease' named entity 'relapse' named entity 'autologous stem cell transplantation' named entity 'interleukin' named entity 'ASCT' named entity 'THERAPY' named entity 'time' named entity 'therapy' named entity 'stem cell' named entity 'IL-2' named entity 'postulated' named entity 'relapse' named entity 'reduce' named entity 'IMMUNOTHERAPY' named entity 'REDUCE' named entity 'study' named entity 'phase I' named entity 'hematologic malignancy' named entity 'AUTOLOGOUS STEM CELL TRANSPLANTATION' named entity 'INTERLEUKIN-2 ' named entity 'HEMATOLOGIC MALIGNANCY' named entity 'STUDY' named entity 'PHASE I' nodeID://b56172330 nodeID://b56172358 nodeID://b56172910 nodeID://b56181794 nodeID://b56186834 nodeID://b56207058 nodeID://b56219774 nodeID://b56240842 nodeID://b56256710 nodeID://b56256734 nodeID://b56257334 nodeID://b56280862 nodeID://b56297438 nodeID://b56315274 nodeID://b56345690 nodeID://b56347286 nodeID://b56347298 nodeID://b56388602 nodeID://b57055310 nodeID://b57065706 nodeID://b57252986 nodeID://b57562450 nodeID://b57726546 nodeID://b58113810
is wasQuotedFrom of	covid:arg/95004cd43f731cf90a3b02353eb1ff77fc2e5784/2 covid:arg/95004cd43f731cf90a3b02353eb1ff77fc2e5784/0 covid:arg/95004cd43f731cf90a3b02353eb1ff77fc2e5784/1 covid:arg/95004cd43f731cf90a3b02353eb1ff77fc2e5784/3
is part of of	covid:95004cd43f731cf90a3b02353eb1ff77fc2e5784#body_text The success of autologous stem cell transplantation (ASCT) for hematologic malignancy is limited largely by a high relapse rate. It is postulated that IL-2 administered after ASCT may eliminate minimal residual disease and thereby reduce relapses. A phase I/II study was performed to identify a regimen of IL-2 (Chiron) that could be given early after ASCT in phase III trials. In the phase I study, beginning a median of 46 days after ASCT for hematologic malignancy, cohorts of three to four patients received escalating doses of ‘induction’ IL-2 of 9, 10, or 12 × 10(6) IU/m(2)/day for 4 or 5 days by continuous i.v. infusion (CIV), followed by a 4-day rest period, and then 1.6 × 10(6) IU/m(2)/day of maintenance IL-2 by CIV for 10 days. The maximum tolerated dose (MTD) of induction IL-2 was 9 × 10(6) IU/m(2)/day × 4. In the phase II study, 52 patients received the MTD. Eighty percent of patients completed induction IL-2. Most patients exhibited some degree of capillary leak. One patient died of CMV pneumonia and one died of ARDS. Maintenance IL-2 was well tolerated. In the phase I/II study, 16 of 31 patients with non-Hodgkin lymphoma (NHL), 3/8 with Hodgkin disease (HD), 4/17 with AML, and 4/5 with ALL remain in CR. Two of six multiple myeloma (MM) patients remain in PR. Although the regimen of IL-2 identified had significant side-effects in some patients, it was well tolerated in the majority of patients. Phase III prospectively randomized clinical trials are in progress to determine if this IL-2 regimen will decrease the relapse rate after ASCT for AML and NHL.

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software